SCHEMBL9890732

SCHEMBL9890732

CNC(=O)Cc1ccc(F)cc1-c1ccccc1F

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.43
LMNA P02545 1/20 0.41
RAB9A P51151 1/20 0.41
SMN1; SMN2 Q16637 3/20 0.40
KIF11 P52732 1/20 0.40
KCNA5 P22460 2/20 0.40
KCNK3 O14649 1/20 0.40
KCNK5 O95279 1/20 0.40
KCNK17 Q96T54 1/20 0.40
KCNK9 Q9NPC2 1/20 0.40
ADORA2A P29274 3/20 0.40
ADORA1 P30542 3/20 0.40
ADORA3 P0DMS8 2/20 0.40
ADORA2B P29275 1/20 0.40
MPO P05164 1/20 0.40
CHRM3 P20309 1/20 0.39
SIGMAR1 Q99720 1/20 0.39
CXCL8 P10145 1/20 0.39
PPIA P62937 1/20 0.39
P2RX7 Q99572 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2395717 0.89 SMN1; SMN2 (0.43) ALDH1A1LMNARAB9ASMN1; SMN2KIF11
SCHEMBL2395314 0.86 RAB9A (0.49) ALDH1A1LMNARAB9ASMN1; SMN2ADORA2A
SCHEMBL2395234 0.86 CNR1 (0.43) ALDH1A1LMNARAB9ASMN1; SMN2CHRM3
SCHEMBL9890786 0.85 RAB9A (0.43) ALDH1A1LMNARAB9ASMN1; SMN2ADORA2A
SCHEMBL9890731 0.84 LMNA (0.48) ALDH1A1LMNARAB9ASMN1; SMN2KIF11
SCHEMBL9890652 0.82 CXCL8 (0.50) CXCL8
SCHEMBL9890752 0.82 SMN1; SMN2 (0.42) ALDH1A1LMNARAB9ASMN1; SMN2KCNA5
SCHEMBL2395132 0.81 ICMT (0.39) ALDH1A1MPOCHRM3MAPT
SCHEMBL9890765 0.80 SMN1; SMN2 (0.43) LMNARAB9ASMN1; SMN2MPOCHRM3
SCHEMBL13329783 0.80 MAPK8 (0.52) ALDH1A1SMN1; SMN2MPOSIGMAR1P2RX7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2012-06-07 US disclosed
EP-2374790-A1 BIPHENYLACETAMIDE DERIVATIVE Dainippon Sumitomo Pharma Co., Ltd. (JP) 2011-10-12 EP disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120142771-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ALDH1A1 576/4885LMNA 3980/4885RAB9A 208/4885
US-20110224304-A1 BIPHENYLACETAMIDE DERIVATIVE HRH3, KCNH3, BRPF3 ALDH1A1 576/4885LMNA 3980/4885RAB9A 208/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.